HomeBUSINESS
BUSINESS

Novartis Japan Chief Sees CAR-T Pricing as “Important Issue” Here Too
(Sep.29.2017)

Novartis Pharma President Kazunari Tsunaba
Novartis AG’s Japan helmsman Kazunari Tsunaba is bracing for a challenge he will face on the pricing of the company’s chimeric antigen receptor T cell (CAR-T) therapy in his country, as its US$475,000 price tag and outcome-based arrangement is stirring hot debates on the other side of the Pacific ...
(LOG IN FOR FULL STORY)

News Calendar